Table 1.
Efficacy and safety of mepolizumab in asthma and other eosinophilic diseases
| Disease | Efficacy | Safety profile |
|---|---|---|
| Asthma | Mepolizumab reduces peripheral blood eosinophilia, percentage of bone marrow eosinophils, airway eosinophils, and rate of exacerbations in almost all RCTs. Improvements in FEV1 were found in only two studies13,36 | No relevant AE |
| HES | Primary end points achieved | No relevant AE |
| EGBPA | Primary end points achieved | No relevant AE |
| Eosinophilic esophagitis | Primary end points not achieved | No relevant AE |
| Nasal polyposis | Primary end points achieved | No relevant AE |
| Atopic dermatitis | Primary end points not achieved | No relevant AE |
| COPD | Ongoing RCTs | No data available at the time |
Abbreviations: HES, hypereosinophilic syndrome; EGBPA, eosinophilic granulomatosis with polyangiitis; AE, adverse event; RCTs, randomized clinical trials; FEV1, forced expiratory volume in 1 second.